Quince Therapeutics (QNCX) News Today → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free QNCX Stock Alerts $0.90 -0.01 (-1.09%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | investorplace.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024May 13, 2024 | businesswire.comQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 6, 2024 | businesswire.comQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceApril 25, 2024 | finance.yahoo.comQuince Therapeutics, Inc. (QNCX)April 2, 2024 | investorplace.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023April 1, 2024 | finance.yahoo.comQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsFebruary 22, 2024 | finance.yahoo.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 22, 2024 | businesswire.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 15, 2024 | finance.yahoo.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsFebruary 15, 2024 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Sees Significant Drop in Short InterestQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 1,900,000 shares, a decrease of 7.3% from the January 15th total of 2,050,000 shares. Currently, 6.0% of the company's shares are sold short. Based on an average trading volume of 91,100 shares, the days-to-cover ratio is presently 20.9 days.February 15, 2024 | businesswire.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsFebruary 14, 2024 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Stock Price Down 8.5%Quince Therapeutics (NASDAQ:QNCX) Stock Price Down 8.5%January 4, 2024 | finance.yahoo.comQuince Therapeutics to Participate at Investor Events in January 2024November 11, 2023 | morningstar.comQuince Therapeutics Inc QNCXOctober 27, 2023 | benzinga.comChief Business Officer and COO at Quince Therapeutics Acquires Company Stock Options Worth 75,000 SharesOctober 25, 2023 | benzinga.comQuince Therapeutics Chief Scientific Officer Awarded $291K Worth of Stock OptionsOctober 23, 2023 | finance.yahoo.comQuince Therapeutics Completes Acquisition of EryDel S.p.A.September 28, 2023 | msn.comFDA lifts partial clinical hold on EryDel lead product EryDexSeptember 28, 2023 | finance.yahoo.comU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaSeptember 7, 2023 | benzinga.comQuince Therapeutics President Awarded $692K Worth of Stock OptionsSeptember 6, 2023 | bizjournals.comDaily Digest: Currys aim to raise $50M for Oakland schools; Sotheby's opens new officeSeptember 6, 2023 | finance.yahoo.comQuince Therapeutics Appoints Dr. Charles S. Ryan as PresidentAugust 18, 2023 | benzinga.com325K Reasons To Be Bullish On Quince Therapeutics StockAugust 14, 2023 | benzinga.comQuince Therapeutics And 2 Other Stocks Under $3 Insiders Are BuyingAugust 11, 2023 | finance.yahoo.comQuince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023July 26, 2023 | finanznachrichten.deQUINCE THERAPEUTICS INCJuly 24, 2023 | benzinga.comWhat's Going On With Quince Therapeutics Stock TodayJuly 24, 2023 | finance.yahoo.comQuince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales OpportunityJuly 13, 2023 | msn.comEcho Lake bumps up bid to buy Quince Therapeutics to $1.80July 13, 2023 | seekingalpha.comEcho Lake bumps up bid to buy Quince Therapeutics to $1.80/shareJuly 13, 2023 | finance.yahoo.comEcho Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.June 6, 2023 | finanznachrichten.deEcho Lake Capital: Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder ValueJune 6, 2023 | finance.yahoo.comEcho Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder ValueApril 11, 2023 | finance.yahoo.comQuince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake CapitalApril 6, 2023 | seekingalpha.comQuince Therapeutics: A Company Without A Suitable PlanApril 6, 2023 | bizjournals.comCash-rich life sciences companies are targets. Activist investors are taking aim.April 6, 2023 | finance.yahoo.comQuince Therapeutics Engages MTS Health Partners as Independent Financial AdvisorApril 5, 2023 | seekingalpha.comQuince Therapeutics adopts poison pill amid unsolicited takeover offerApril 5, 2023 | finance.yahoo.comQuince Therapeutics Adopts Limited Duration Stockholders Rights PlanMarch 22, 2023 | businesswire.comQuince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake CapitalMarch 21, 2023 | benzinga.comQuince Therapeutics shares are trading higher after Echo Lake Capital offered to acquire the company for $1.60 per share in cash.March 21, 2023 | msn.comQuince stock surges ~50% on acquisition offer from Echo Lake CapitalMarch 21, 2023 | finance.yahoo.comEcho Lake Capital Offers to Acquire Quince Therapeutics, Inc.January 30, 2023 | msn.comQuince expects ~$11M annual capital and operating expenditures in 2023January 30, 2023 | finance.yahoo.comQuince Therapeutics Provides Pipeline Update and Business Outlook for 2023January 27, 2023 | bizjournals.comCasey Lynch and her Cortexyme team regroup at Lighthouse for another shot at Alzheimer'sJanuary 27, 2023 | investorplace.comWhy Is Quince Therapeutics (NASDAQ:QNCX) Stock Up 53% Today?January 27, 2023 | finance.yahoo.comQuince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse PharmaceuticalsJanuary 15, 2023 | barrons.comQuince Therapeutics Inc.November 21, 2022 | finance.yahoo.comWe Think Quince Therapeutics (NASDAQ:QNCX) Needs To Drive Business Growth Carefully Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made … Click here to see the presentation now. QNCX Media Mentions By Week QNCX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNCX News Sentiment▼0.870.49▲Average Medical News Sentiment QNCX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNCX Articles This Week▼40▲QNCX Articles Average Week Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MiNK Therapeutics News Cyclo Therapeutics News SAB Biotherapeutics News Achilles Therapeutics News OKYO Pharma News Pluri News Dyadic International News Brainstorm Cell Therapeutics News Surrozen News IN8bio News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNCX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
